An ideal model for the study of liver disease would combine the expansion capacity and phenotypic stability of hepatoma cell lines with the functionality and normal karyotype of primary hepatocytes. Human induced pluripotent stem cell-derived hepatocyte-like cells (HLCs) have the potential to fulfil this niche.
DefiniGEN’s proprietary differentiation protocol permits large-scale generation of HLCs with field leading purity and functionality. Importantly, the HLCs successfully recapitulate key aspects of disease pathophysiology across a wide- range of conditions that affect different aspects of liver function.
For rare forms of liver disease, identifying patients with a genomic mutation of interest is challenging. CRISPR/ Cas9 can be used with high editing efficiency in iPSCs when compared to primary cell types. In practice, this means specific mutations associated with liver disease can be precisely introduced to iPSCs with relative ease, before expansion and subsequent differentiation to HLCs. This approach allows for the study of rare monogenic diseases and polymorphisms that increase susceptibility to types of liver disease previously inaccessible to researchers.
Frequently asked questions
Do the hepatocyte-like-cells express ASGR1?
Yes, ASGR1 and ASGR2 has been detected by qPCR analysis and ICC and has been shown to localize on the cell membrane.
Do they have a functional urea cycle?
Yes this has been characterized by gene expression profiling, Western blot analysis and Ornithine stimulated functional analysis.
Can you see CYP expression activity?
Expression of CYPs is detectable by qPCR analysis, but they are lower than Primary Human Hepatocytes (PHH).